Evidence map›Paper›PMID 42368097›Full record

ArticleACS omega2026

Sustainable Fragment Peptide Synthesis (SFPS): Leveraging Oxyma as a Dual Resin Cleavage-Peptide Coupling Agent.

Jan Pawlas

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jan PawlasPolyPeptide, Limhamnsvägen 108, PO BOX 30089, 20061 Limhamn, Sweden.ORCID https://orcid.org/0000-0002-8151-4112

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coupling of fully protected peptide fragments (FPPFs) released off acid labile polymer supports such as 2-chlorotrityl chloride (CTC) resin is a powerful peptide synthesis approach used from R&D to manufacturing type 2 diabetes/obesity drugs on a ton scale. Nevertheless, cleavage of acid labile FPPF resins typically entails PFAS-classified TFA as a reagent and suspected carcinogen DCM as a solvent while necessitating laborious work-ups and isolations. Here, in an approach we term sustainable fragment peptide synthesis (SFPS), a cleavage of FPPFs off 2-chlorotrityl (2-CT) resin was carried out using coupling additive ethyl cyanohydroxyiminoacetate (Oxyma) in EtOAc. The cleaved FPPF was not isolated but rather coupled with another peptide resin using a carbodiimide as a coupler and Oxyma from the cleavage as an additive. Showcasing the power of SFPS, a two Cys-(Trt) containing FPPF resin formed by a process leveraging Oxyma as a dual cleavage-coupling agent was cyclized to a disulfide containing FPPF resin which upon an Oxyma-induced cleavage afforded a disulfide containing FPPF, opening the door to the world of modular SFPS as a means of accessing a variety of complex peptide architectures.

Identifiers

PMID42368097
PMCPMC13295053

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.